162 related articles for article (PubMed ID: 18321155)
1. Emerging drugs for complications of end-stage liver disease.
Dowman JK; Holt AP; Newsome PN; Adams DH
Expert Opin Emerg Drugs; 2008 Mar; 13(1):159-74. PubMed ID: 18321155
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
[TBL] [Abstract][Full Text] [Related]
4. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
Vargas JI; Arrese M; Shah VH; Arab JP
Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
[TBL] [Abstract][Full Text] [Related]
5. Pathobiology of liver fibrosis: a translational success story.
Lee YA; Wallace MC; Friedman SL
Gut; 2015 May; 64(5):830-41. PubMed ID: 25681399
[TBL] [Abstract][Full Text] [Related]
6. Developing strategies for liver fibrosis treatment.
Murphy F; Arthur M; Iredale J
Expert Opin Investig Drugs; 2002 Nov; 11(11):1575-85. PubMed ID: 12437504
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology applications for the therapy of liver fibrosis.
Giannitrapani L; Soresi M; Bondì ML; Montalto G; Cervello M
World J Gastroenterol; 2014 Jun; 20(23):7242-51. PubMed ID: 24966595
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for liver fibrosis.
Fowell AJ; Iredale JP
Dig Dis; 2006; 24(1-2):174-83. PubMed ID: 16699275
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic Therapies: Where Are We Now?
Yoon YJ; Friedman SL; Lee YA
Semin Liver Dis; 2016 Feb; 36(1):87-98. PubMed ID: 26870935
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
Friedman SL
Nat Clin Pract Gastroenterol Hepatol; 2004 Dec; 1(2):98-105. PubMed ID: 16265071
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Fibrosis: Emerging Therapies.
Friedman SL
Dig Dis; 2015; 33(4):504-7. PubMed ID: 26159266
[TBL] [Abstract][Full Text] [Related]
12. Development and Regression of Cirrhosis.
Saffioti F; Pinzani M
Dig Dis; 2016; 34(4):374-81. PubMed ID: 27170391
[TBL] [Abstract][Full Text] [Related]
13. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
Nishikawa K; Osawa Y; Kimura K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
[TBL] [Abstract][Full Text] [Related]
14. Hepatic fibrosis: Concept to treatment.
Trautwein C; Friedman SL; Schuppan D; Pinzani M
J Hepatol; 2015 Apr; 62(1 Suppl):S15-24. PubMed ID: 25920084
[TBL] [Abstract][Full Text] [Related]
15. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
Lanini S; Scognamiglio P; Mecozzi A; Lombardozzi L; Vullo V; Angelico M; Gasbarrini A; Taliani G; Attili AF; Perno CF; De Santis A; Puro V; Cerqua F; D'Offizi G; Pellicelli A; Armignacco O; Mennini FS; Siciliano M; Girardi E; Panella V; Ippolito G;
BMC Infect Dis; 2018 May; 18(1):223. PubMed ID: 29769038
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic therapy in chronic liver disease.
Rockey DC
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):95-107. PubMed ID: 15704042
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for idiopathic pulmonary fibrosis.
Thannickal VJ; Flaherty KR; Hyzy RC; Lynch JP
Expert Opin Emerg Drugs; 2005 Nov; 10(4):707-27. PubMed ID: 16262559
[TBL] [Abstract][Full Text] [Related]
18. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.
Popov Y; Schuppan D
Hepatology; 2009 Oct; 50(4):1294-306. PubMed ID: 19711424
[TBL] [Abstract][Full Text] [Related]
19. Prostacyclin in liver disease: a potential therapeutic option.
Zardi EM; Dobrina A; Amoroso A; Afeltra A
Expert Opin Biol Ther; 2007 Jun; 7(6):785-90. PubMed ID: 17555364
[TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis: Common mechanisms and antifibrotic therapies.
Schuppan D
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S51-9. PubMed ID: 26189980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
